Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

Tolar, Jakub

Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. [electronic resource] - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Jul 2012 - 1007-11 p. digital

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

1523-6536

10.1016/j.bbmt.2012.04.014 doi


Acute Disease
Adolescent
Adult
Aged
Anemia, Aplastic--mortality
Antilymphocyte Serum--administration & dosage
Antineoplastic Agents--administration & dosage
Bone Marrow Transplantation
Child
Cyclophosphamide--administration & dosage
Drug Administration Schedule
Drug Dosage Calculations
Female
Humans
Male
Middle Aged
Survival Rate
Transplantation Conditioning
Unrelated Donors
Vidarabine--administration & dosage
Whole-Body Irradiation--adverse effects